학술논문

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, October 2020, 21(10):1283-1295)
Subject
Language
English
ISSN
14745488
14702045